Zou Zhi, Hu Wenhui, Kang Fei, Xu Zhonghua, Li Yuheng, Zhang Jing, Li Jianmei, Zhang Yuan, Dong Shiwu
College of Bioengineering, Chongqing University, Chongqing 400044, China; Department of Biomedical Materials Science, College of Biomedical Engineering, Third Military Medical University (Army Medical University), Chongqing 400038, China.
Department of Biomedical Materials Science, College of Biomedical Engineering, Third Military Medical University (Army Medical University), Chongqing 400038, China.
J Adv Res. 2025 Mar;69:515-529. doi: 10.1016/j.jare.2024.04.012. Epub 2024 Apr 14.
Osteoarthritis (OA) is a devastating whole-joint disease affecting a large population worldwide; the role of lipid dysregulation in OA and mechanisms underlying targeted therapy effect of lipid-lowering metformin on OA remains poorly defined.
To investigate the effects of lipid dysregulation on OA progression and to explore lipid dysregulation-targeting OA treatment of metformin.
RNA-Seq data, biochemical, and histochemical assays in human and murine OA cartilage as well as primary chondrocytes were utilized to determine lipid dysregulation. Effects of metformin, a potent lipid-lowering medication, on ACSL4 expression and chondrocyte metabolism were determined. Further molecular experiments, including RT-qPCR, western blotting, flow cytometry, and immunofluorescence staining, were performed to investigate underlying mechanisms. Mice with intra-articular injection of metformin were utilized to determine the effects on ACLT-induced OA progression.
ACSL4 and 4-HNE expressions were elevated in human and ACLT-induced mouse OA cartilage and IL-1β-treated chondrocytes (P < 0.05). Ferrostatin-1 largely rescued IL-1β-induced MDA, lipid peroxidation, and ferroptotic mitochondrial morphology (P < 0.05). Metformin decreased the levels of OA-related genes (P < 0.05) and increased the levels of p-AMPK and p-ACC in IL-1β-treated chondrocytes. Intra-articular injection of metformin alleviated ACLT-induced OA lesions in mice, and reverted the percentage of chondrocytes positive for MMP13, Col2a1, ACSL4 and 4-HNE in ACLT mice (P < 0.05). Ferroptotic chondrocytes promoted the recruitment and chemotaxis of RAW264.7 cells via CCL2, which was blocked by metformin in vitro (P < 0.05).
We establish a critical role of polyunsaturated fatty acids metabolic process in OA cartilage degradation and define metformin as a potential OA treatment. Metformin reshapes lipid availability and ameliorates chondrocyte ferroptosis sensitivity via the AMPK/ACC pathway. In the future, gene-edited animals and extensive omics technologies will be utilized to reveal detailed lipids' involvement in cartilage lesions.
骨关节炎(OA)是一种严重的全关节疾病,影响着全球大量人口;脂质代谢失调在OA中的作用以及降脂药物二甲双胍对OA的靶向治疗效果的潜在机制仍不清楚。
研究脂质代谢失调对OA进展的影响,并探索针对脂质代谢失调的二甲双胍对OA的治疗作用。
利用人类和小鼠OA软骨以及原代软骨细胞的RNA测序数据、生化和组织化学分析来确定脂质代谢失调情况。确定强效降脂药物二甲双胍对ACSL4表达和软骨细胞代谢的影响。进行了包括RT-qPCR、蛋白质印迹、流式细胞术和免疫荧光染色在内的进一步分子实验,以研究潜在机制。利用关节内注射二甲双胍的小鼠来确定其对前交叉韧带切断(ACLT)诱导的OA进展的影响。
在人类和ACLT诱导的小鼠OA软骨以及白细胞介素-1β(IL-1β)处理的软骨细胞中,ACSL4和4-羟基壬烯醛(4-HNE)的表达升高(P<0.05)。铁死亡抑制因子-1在很大程度上挽救了IL-1β诱导的丙二醛(MDA)、脂质过氧化和铁死亡线粒体形态(P<0.05)。二甲双胍降低了IL-1β处理的软骨细胞中OA相关基因的水平(P<0.05),并增加了p-AMPK和p-ACC的水平。关节内注射二甲双胍减轻了ACLT诱导的小鼠OA病变,并使ACLT小鼠中基质金属蛋白酶13(MMP13)、Ⅱ型胶原α1(Col2a1)、ACSL4和4-HNE阳性软骨细胞的百分比恢复正常(P<0.05)。铁死亡的软骨细胞通过趋化因子配体2(CCL2)促进RAW264.7细胞的募集和趋化作用,在体外这一作用被二甲双胍阻断(P<0.05)。
我们确立了多不饱和脂肪酸代谢过程在OA软骨降解中的关键作用,并将二甲双胍定义为一种潜在的OA治疗药物。二甲双胍通过AMPK/ACC途径重塑脂质可用性并改善软骨细胞铁死亡敏感性。未来,将利用基因编辑动物和广泛的组学技术来揭示脂质在软骨病变中的详细作用。